KNW Know Labs Inc

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2023.

Financial Highlights:

• In Q1 FY 2024, Know Labs reported a net loss of $3.45 million dollars, compared to a net loss of $3.82 million dollars in Q1 FY 2023, a reduction in net loss of 9.8%. This translates to Earnings Per Share of a loss of $0.04, better than the prior year quarter Earnings Per Share Loss of $0.08, an improvement of 50%, before preferred stock dividends.
• Recorded a non-cash charge to earnings of $792,000 principally related to stock-based compensation of $699,000.
• Research and development expense for Q1 FY2024 was $1.48 million dollars as compared to $1.74 million dollars in Q1 FY 2023, a decrease of 14.7% year over year. The decrease in R&D expense was related to decreased personnel and the use of external consultants to reduce the cost of product development.
• Selling, general and administrative expenses for Q1 FY 2024 was $2.01 million, which was higher by $106,000 than the $1.91 million dollars in the year ago period, an increase of 5.6%.
• As of December 31, 2023, we had cash and cash equivalents of $4.82 million dollars, as compared to $8.02 million at the end of September 30, 2023. Net cash used in operations for Q1 FY 2024 was $3.39 million dollars compared with $2.92 million in Q1 FY 2023.
• During the year ended September 30, 2023, the Company made adjustments to its fixed expenses and the impact of those adjustments has significantly reduced our monthly burn rate. Given the significant reduction in fixed expenses, the Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least June 30, 2024. As we have stated in our Q1 FY 2024 10-Q, we expect to raise additional funds through the issuance of equity, preferred stock and convertible debentures. To that end, we filed an $18 million S-3 shelf registration statement on December 22, 2023, which was subsequently declared effective on January 11, 2024.
• Shareholder equity for Q1 FY 2024 was $1.23 million versus $3.74 million in fiscal year 2023, ending September 30, 2023.

As previously disclosed in its annual report on Form 10-K for the fiscal year ended September 30, 2023, which was filed with the Securities and Exchange Commission on December 19, 2023, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the New York Stock Exchange's Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification. This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.

Conference Call:

Know Labs will host an audio webcast to discuss its results and provide a business update today, February 14, 2024, at 4:30 pm ET (1:30 pm PT). The live webcast will be available on the Investors page of the Company’s website, www.knowlabs.co/investors, and a replay will be available for six months.

Participant Dial-In: 877-514-3621 / +1 215-268-9856

Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=u3gcCI6A

A copy of the form 10-Q filed with the SEC can also be downloaded from the Company’s website.

Income Statement:

KNOW LABS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS   Three Months Ended, December 31, 2023 December 31, 2022   OPERATING EXPENSES- RESEARCH AND DEVELOPMENT EXPENSES $

1,486,388

 

$

1,743,051

 

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

2,011,246

 

1,905,071

 

Total operating expenses

3,497,634

 

3,648,122

 

OPERATING LOSS

(3,497,634

)

(3,648,122

)

  OTHER INCOME (EXPENSE), NET Interest income

51,010

 

-

 

Interest expense

-

 

(227,170

)

Other (expense) income, net

-

 

52,433

 

Total other income (expense), net

51,010

 

(174,737

)

  LOSS BEFORE INCOME TAXES

(3,446,624

)

(3,822,859

)

  Income tax expense

-

 

-

 

  NET LOSS

(3,446,624

)

(3,822,859

)

  Deemed dividends on Series C and D Preferred Stock

(63,629

)

-

 

  NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $

(3,510,253

)

$

(3,822,859

)

  Basic and diluted loss per share $

(0.04

)

$

(0.08

)

  Weighted average shares of common stock outstanding- basic and diluted

81,094,007

 

48,187,339

 

Balance Sheet:

KNOW LABS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS   December 31, 2023 9/30/2023 (1) ASSETS Unaudited   CURRENT ASSETS: Cash and cash equivalents $

4,821,477

 

$

8,023,716

 

Total current assets

4,821,477

 

8,023,716

 

  PROPERTY AND EQUIPMENT, NET

75,298

 

81,325

 

  OTHER ASSETS Other assets

18,767

 

15,766

 

Operating lease right-of-use asset

97,567

 

145,090

 

  TOTAL ASSETS $

5,013,109

 

$

8,265,897

 

  LIABILITIES AND STOCKHOLDERS' EQUITY   CURRENT LIABILITIES: Accounts payable - trade $

627,058

 

$

1,292,861

 

Accrued expenses

95,952

 

94,062

 

Accrued expenses - related parties

196,241

 

218,334

 

Convertible notes payable, net

2,761,931

 

2,761,931

 

Current portion of operating lease right-of-use liability

106,038

 

154,797

 

Total current liabilities

3,787,220

 

4,521,985

 

  COMMITMENTS AND CONTINGENCIES (Note 11)

-

 

-

 

  STOCKHOLDERS' EQUITY Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows: Series C Convertible Preferred stock $0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 12/31/2023 and 9/30/2023, respectively

1,790

 

1,790

 

Series D Convertible Preferred stock $0.001 par value, 20,000 shares authorized, 10,161 shares issued and outstanding at 12/31/2023 and 9/30/2023, respectively

1,015

 

1,015

 

Common stock - $0.001 par value, 200,000,000 shares authorized, 81,346,524 and 80,358,463 shares issued and outstanding at 12/31/2023 and 9/30/2023, respectively

81,347

 

80,358

 

Additional paid in capital

126,492,778

 

125,501,537

 

Accumulated deficit

(125,351,041

)

(121,840,788

)

Total stockholders' equity

1,225,889

 

3,743,912

 

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $

5,013,109

 

$

8,265,897

 

Cash Flow:

KNOW LABS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS   Three Months Ended, December 31, 2023 December 31, 2022   CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $

(3,446,624

)

$

(3,822,859

)

Adjustments to reconcile net loss to net cash (used in) operating activities Depreciation and amortization

18,724

 

103,160

 

Stock based compensation - stock option grants

699,246

 

744,640

 

Issuance of common stock for services

26,250

 

-

 

Amortization of operating lease right-of-use asset

47,523

 

44,404

 

Interest expense for extension of notes and warrants

-

 

206,994

 

Changes in operating assets and liabilities: Other long-term assets

(3,001

)

(1,998

)

Operating lease right-of-use liability

(48,759

)

(45,732

)

Accounts payable - trade and accrued expenses

(686,006

)

(146,026

)

NET CASH (USED IN) OPERATING ACTIVITIES

(3,392,647

)

(2,917,417

)

  CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of research and development equipment

(12,697

)

(10,846

)

NET CASH (USED IN) INVESTING ACTIVITIES:

(12,697

)

(10,846

)

  CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock offering, net

203,105

 

-

 

Proceeds from issuance of common stock for stock options exercise

-

 

2,343

 

Proceeds from issuance of common stock for warrant exercise

-

 

12,500

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

203,105

 

14,843

 

  NET (DECREASE) IN CASH AND CASH EQUIVALENTS

(3,202,239

)

(2,913,420

)

  CASH AND CASH EQUIVALENTS, beginning of period

8,023,716

 

12,593,692

 

  CASH AND CASH EQUIVALENTS, end of period $

4,821,477

 

$

9,680,272

 

  Supplemental disclosures of cash flow information: Interest paid $

-

 

$

-

 

Taxes paid $

-

 

$

-

 

  Supplemental disclosure of non-cash financing activity: Deemed dividends on Series C and D Preferred Stock $

63,629

 

$

-

 

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214439657/en/

For Know Labs Media Inquiries Contact: Matter Health Abby Mayo Knowlabs@matternow.com Ph. (617) 272-0592 Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co Ph. (206) 629-6414